Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors |
| [10-September-2026] |
Former Incyte Executive Brings Extensive Oncology, Corporate Strategy, Business Development and Medical Affairs Experience MORRISTOWN, N.J., Sept. 10, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody-drug conjugate (ADC) cancer treatments, today announced the appointment of Vijay Iyengar, MD, to its Board of Directors, effective September 9, 2026. Dr. Iyengar brings more than two decades of oncology experience building and scaling global businesses, leading strategic transactions across development-stage and commercial assets and guiding product portfolios from early development through commercialization. During his nine years in senior leadership roles at Incyte Corporation, he helped drive transformative change, including the launch of five brands across eight indications, the company's expansion into more than 20 countries and growth from approximately $1B to more than $4B in annual revenue. "I'm pleased to welcome Vij to the Board at this important stage of Whitehawk's growth," said Dave Lennon, PhD, President and Chief Executive Officer of Whitehawk Therapeutics. "His expansive leadership experience in oncology will be valuable as we continue to advance our clinical programs, expand our ADC portfolio and make disciplined decisions about how best to develop and realize the potential of our pipeline." Prior to joining Incyte, Dr. Iyengar held senior leadership positions in oncology at Novartis. Earlier in his career, he was an Engagement Manager in the healthcare practice at McKinsey & Company. Dr. Iyengar received a BS in Biology from Stanford University and an MD from Harvard Medical School. "I was drawn to Whitehawk for its strong foundation built on scientific rigor and a clear strategic vision," said Dr. Iyengar. "I look forward to working with the leadership team and my fellow directors to help guide Whitehawk through its next phase as they work to bring new ADC treatments to patients with cancer." About Whitehawk Therapeutics Whitehawk's underlying ADC platform leverages CPT113 as the core linker-payload technology, enhanced with its proprietary Carbon Bridge Cysteine Re-pairing (CBCR) bioconjugation process to support improved stability and therapeutic index. Whitehawk has an option agreement with Hangzhou DAC for access to CPT113 for use in up to five additional ADC programs. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn. Forward-Looking Statements Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, including under the caption "Item 1A. Risk Factors," and in Whitehawk's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Whitehawk's reports and other documents that Whitehawk has filed, or will file, with the SEC from time to time and available at www.sec.gov. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Whitehawk undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact:
SOURCE Whitehawk Therapeutics, Inc. | ||
Company Codes: NASDAQ:WHWK |
View original content to download multimedia:
